Science Journals In Novel Biomarker|OMICS International|Journal Of Molecular Biomarkers And Diagnosis

Our Group organises 3000+ Global Conferenceseries Events every year across USA, Europe & Asia with support from 1000 more scientific societies and Publishes 700+ Open Access Journals which contains over 50000 eminent personalities, reputed scientists as editorial board members.

Science Journals In Novel Biomarker

Science Journals are multidimensional Open Access gateways for the exploration of scientific discoveries and new research in the medical and other sciences. These journals are periodical publications intended to communicate with the scientific community to further the progress of mankind. Science Journals represent the collaborative efforts of many scientists and scholars from various disciplines. Pharmaceutical research is undergoing a profound change. The deluge of molecular data and the advent of computational approaches to analyze them have revolutionized the traditional process of discovering drugs by happenstance in natural products or synthetizing and screening large libraries of small molecule compounds. Today, computational methods permeate so many aspects of pharmaceutical research that one can say that drugs are “designed” rather than “discovered”. In order to explore the power of semantic machine intelligence for the screening of a collection of research documents in search of unknown/novel information relevant to early-stage drug candidate discovery and development, a pilot experiment in which the InfoCodex semantic engine was used for the specific task to discover unknown/novel biomarkers and phenotypes for diabetes and/or obesity (D&O) by semantic machine analysis of diverse and numerous biomedical research texts.The pilot experiment was focused on biomarkers and phenotypes since these play a paramount role in modern medicine. Drugs of the future will be targeted to populations and groups of individuals with common biological characteristics predictive of drug efficacy and/or toxicity. This practice is called “individualized medicine” or “personalized medicine”. The revealing features are called “biomarkers” and “phenotypes”. The human assessment of valuable and irrelevant novel candidates is thus the most crucial evaluation. The objective of the experiment was not a statistically significant certification of a specific biomarker, but it was a proof-of-concept for the automatic discovery of novel biomarkers/phenotypes. Nevertheless, precision and recall measures were estimated to provide at least a qualitative indication of emerging trends. (Trugenberger CA, Peregrim D, Discovery of Novel Biomarkers by Text Mining: A New Avenue for Drug Research?)
  • Share this page
  • Facebook
  • Twitter
  • LinkedIn
  • Google+
  • Pinterest
  • Blogger

Last date updated on February, 2021